Apogee Therapeutics landed a major non-dilutive capital package from Blackstone Life Sciences to push zumilokibart (anti-IL-13) into phase 3 for atopic dermatitis. The deal provides up to $1.3 billion, structured as a royalty financing component and senior corporate debt, with milestone-based triggers tied to phase 3 progress and FDA approval. Apogee’s financing announcement follows additional trial signals, including 16-week induction data from Part B of its phase 2 APEX program in moderate-to-severe atopic dermatitis. The company reported 65.9% of patients achieving at least a 75% reduction in eczema severity at the 16-week time point. The funding underscores how investors are underwriting late-stage immunology bets where differentiation and dosing convenience could matter in a competitive biologics landscape. Apogee also said it sees potential expansion beyond dermatitis into other inflammatory indications.